Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Lorraine A. Chantrill

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5790-0208; OpenAlex author ID A5072628958, A5080356780. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
82
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 4 papers · 2016: 1 paper · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 32

  1. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  2. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  3. Chemotherapy and radiotherapy for advanced pancreatic cancer. Co-author DOI 10.1002/14651858.cd011044.pub3↗
  4. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  5. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Co-author DOI 10.1016/j.esmogo.2023.07.001↗
  6. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  7. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  8. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  9. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  10. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk an… Co-author DOI 10.1186/s12885-021-08666-y↗
  11. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  12. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  13. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  14. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. Co-author DOI 10.1016/j.hpb.2018.08.016↗
  15. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  16. Chemotherapy and radiotherapy for advanced pancreatic cancer. Co-author DOI 10.1002/14651858.cd011044.pub2↗
  17. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Last author DOI 10.1111/imj.13810↗
  18. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  19. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  20. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group … Co-author DOI 10.1080/14737140.2017.1369882↗
  21. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  22. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  23. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  24. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Co-author DOI 10.1158/1078-0432.ccr-15-0426↗
  25. Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas. Co-author DOI 10.2174/1568009615666150512102957↗
  26. Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. Co-author DOI 10.3892/mco.2015.533↗
  27. Clinical and pathologic features of familial pancreatic cancer. Co-author DOI 10.1002/cncr.28863↗
  28. Chronic pancreatitis: a path to pancreatic cancer. First author DOI 10.1016/j.canlet.2013.08.015↗
  29. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2013.722↗
  30. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Co-author DOI 10.1186/gm482↗
  31. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  32. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Co-author DOI 10.1093/annonc/mdr561↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adnan M. Nagrial · 11 shared papers, 2012–2024 · strength 0.83
  2. Venessa T. Chin · 10 shared papers, 2012–2024 · strength 0.71
  3. Jaswinder Singh Samra · 10 shared papers, 2012–2021 · strength 0.50
  4. Desmond Yip · 3 shared papers, 2018–2024 · strength 0.43
  5. David Goldstein · 5 shared papers, 2013–2022 · strength 0.39
  6. Andrew Victor Biankin · 8 shared papers, 2012–2020 · strength 0.36
  7. Anthony James Gill · 8 shared papers, 2012–2020 · strength 0.32
  8. Timothy Jay Price · 3 shared papers, 2017–2023 · strength 0.32
  9. Amber L. Johns · 7 shared papers, 2012–2020 · strength 0.27
  10. Marina Pajic · 7 shared papers, 2012–2020 · strength 0.27
  11. David Kuang-Fu Chang · 7 shared papers, 2012–2020 · strength 0.27
  12. Christos Stelios Karapetis · 2 shared papers, 2022–2023 · strength 0.25
  13. Niall Christopher Tebbutt · 2 shared papers, 2022–2023 · strength 0.25
  14. Lucy Haggstrom · 1 shared paper, 2024 · strength 0.24
  15. James G. Kench · 5 shared papers, 2012–2020 · strength 0.23
  16. Val Gebski · 2 shared papers, 2021–2023 · strength 0.23
  17. Jeremy L. Humphris · 6 shared papers, 2012–2020 · strength 0.22
  18. Angela S. Y. Chou · 5 shared papers, 2013–2020 · strength 0.22
  19. Nam Quoc Nguyen · 3 shared papers, 2014–2021 · strength 0.21
  20. Nick Pavlakis · 3 shared papers, 2015–2022 · strength 0.21
  21. Florian Lordick · 2 shared papers, 2017–2022 · strength 0.19
  22. Eva Segelov · 2 shared papers, 2017–2022 · strength 0.19
  23. Ian Chau · 2 shared papers, 2017–2022 · strength 0.19
  24. Mark J. Cowley · 4 shared papers, 2013–2020 · strength 0.18
  25. Neil Donald Merrett · 3 shared papers, 2012–2020 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.